Basilea Pharmaceutica (XSWX:BSLN) Research & Development: CHF105.9 Mil (TTM As of Dec. 2025)


XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
59 GF Score
Price CHF54.70
GF Value CHF57.63
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Research & Development?

Basilea Pharmaceutica XSWX:BSLN -0.55% 59 Research & Development is CHF105.9 Mil as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 59/100 and a GF Value™ of CHF57.63 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Basilea Pharmaceutica's Research & Development for the six months ended in Dec. 2025 was CHF67.6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was CHF105.9 Mil.

Basilea Pharmaceutica  (XSWX:BSLN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Basilea Pharmaceutica Research & Development Related Terms

Basilea Pharmaceutica Research & Development Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Research & Development Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 93.16 73.80 77.85 77.14 105.90

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.39 33.60 43.55 38.29 67.60
XSWX:BSLN
59GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF105.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF105.9 Mil mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Research & Development of CHF105.9 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Research & Development too high?
Basilea Pharmaceutica's current Research & Development is CHF105.9 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Research & Development compare to VRTX and REGN?
Basilea Pharmaceutica's Research & Development of CHF105.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Research & Development is CHF105.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.63, compared to a current price of CHF54.70 — trading 5.1% below its estimated fair value. The current Research & Development is CHF105.9 Mil. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Research & Development is CHF105.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF54.70 is trading 5.1% below its estimated GF Value™ of CHF57.63. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Research & Development: CHF105.9 Mil
  • GF Value™: CHF57.63 vs. price of CHF54.70 (5.1% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
59GF Score

Get the complete analysis for XSWX:BSLN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.70
Price
CHF57.63
GF Value